EFFICACY AND SAFETY OF RANIBIZUMAB FOR THE TREATMENT OF CHOROIDAL NEOVASCULARIZATION DUE TO UNCOMMON CAUSE: Twelve-Month Results of the MINERVA Study (Q38680981)

From Wikidata

Jump to navigation Jump to search

scientific article published on 12 July 2017

Language	Label	Description	Also known as
English	EFFICACY AND SAFETY OF RANIBIZUMAB FOR THE TREATMENT OF CHOROIDAL NEOVASCULARIZATION DUE TO UNCOMMON CAUSE: Twelve-Month Results of the MINERVA Study	scientific article published on 12 July 2017

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

EFFICACY AND SAFETY OF RANIBIZUMAB FOR THE TREATMENT OF CHOROIDAL NEOVASCULARIZATION DUE TO UNCOMMON CAUSE: Twelve-Month Results of the MINERVA Study (English)

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

neovascularization

1 reference

based on heuristic

inferred from title

4

object named as

Frank G Holz

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Timothy Y Y Lai

0 references

author name string

Timothy Y Y Lai

1

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Giovanni Staurenghi

2

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Paolo Lanzetta

3

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Shiao Hui Melissa Liew

5

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Sabine Desset-Brethes

6

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Harry Staines

7

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Philip G Hykin

8

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

MINERVA study group

9

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

publication date

12 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

SIX-YEAR OUTCOMES OF INTRAVITREAL BEVACIZUMAB FOR CHOROIDAL NEOVASCULARIZATION IN PATIENTS WITH PATHOLOGIC MYOPIA.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6086222

15 October 2018

MYOPIC CHOROIDAL NEOVASCULARIZATION: Diagnosis and Treatment.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6086222

15 October 2018

Intravitreal aflibercept for myopic choroidal neovascularization

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6086222

15 October 2018

ANTIANGIOGENICS IN CHOROIDAL NEOVASCULARIZATION ASSOCIATED WITH LASER IN CENTRAL SEROUS CHORIORETINOPATHY.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6086222

15 October 2018

Aflibercept as primary treatment for myopic choroidal neovascularisation: a retrospective study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6086222

15 October 2018

Ranibizumab vs. aflibercept for wet age-related macular degeneration: network meta-analysis to understand the value of reduced frequency dosing

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6086222

15 October 2018

OUTCOMES OF TREATMENT OF CHOROIDAL NEOVASCULARIZATION ASSOCIATED WITH CENTRAL SEROUS CHORIORETINOPATHY WITH INTRAVITREAL ANTIANGIOGENIC AGENTS.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6086222

15 October 2018

Central serous chorioretinopathy: Recent findings and new physiopathology hypothesis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6086222

15 October 2018

Ocular histoplasmosis syndrome.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6086222

15 October 2018

Intravitreal Aflibercept Injection in Patients with Myopic Choroidal Neovascularization: The MYRROR Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6086222

15 October 2018

Bevacizumab for choroidal neovascularization secondary to age-related macular degeneration and pathological myopia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6086222

15 October 2018

Role of Intravitreal Antivascular Endothelial Growth Factor Injections for Choroidal Neovascularization due to Choroidal Osteoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6086222

15 October 2018

Intravitreal bevacizumab for choroidal neovascularization secondary to angioid streaks: a long-term follow-up study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6086222

15 October 2018

RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6086222

15 October 2018

Ranibizumab in myopic choroidal neovascularization: the 12-month results from the REPAIR study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6086222

15 October 2018

Ranibizumab for the treatment of choroidal neovascularisation secondary to pathological myopia: interim analysis of the REPAIR study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6086222

15 October 2018

Five-year visual results of intravitreal bevacizumab in refractory inflammatory ocular neovascularization

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6086222

15 October 2018

Ranibizumab for age-related macular degeneration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6086222

15 October 2018

Long-term effectiveness of intravitreal bevacizumab for choroidal neovascularization secondary to angioid streaks in pseudoxanthoma elasticum.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6086222

15 October 2018

Intravitreal ranibizumab for the treatment of inflammatory choroidal neovascularization

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6086222

15 October 2018

Ranibizumab for choroidal neovascularization secondary to causes other than age-related macular degeneration: a phase I clinical trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6086222

15 October 2018

Inflammatory choroidal neovascularization.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6086222

15 October 2018

Combination therapy with verteporfin and anti-VEGF agents in neovascular age-related macular degeneration: where do we stand?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6086222

15 October 2018

Intravitreal bevacizumab for choroidal neovascularisation secondary to causes other than age-related macular degeneration.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6086222

15 October 2018

Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6086222

15 October 2018

Intravitreal injection of bevacizumab for exsudative AMD with occult or minimal classic choroidal neovascularisation (CNV)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6086222

15 October 2018

Choroidal neovascularisation in children

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6086222

15 October 2018

Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6086222

15 October 2018

Combination therapy for choroidal neovascularisation.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6086222

15 October 2018

Laser photocoagulation for neovascular age-related macular degeneration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6086222

15 October 2018

Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6086222

15 October 2018

Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6086222

15 October 2018

Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6086222

15 October 2018

Ranibizumab for neovascular age-related macular degeneration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6086222

15 October 2018

Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6086222

15 October 2018

The epidemiology of age-related macular degeneration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6086222

15 October 2018

Differential expression of angioregulatory factors in normal and CNV-derived human retinal pigment epithelium

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6086222

15 October 2018

Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6086222

15 October 2018

Photodynamic effects on choroidal neovascularization and physiological choroid

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6086222

15 October 2018

Basal ganglia involvement in sensory and cognitive processing. A depth electrode CNV study in human subjects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6086222

15 October 2018

Choroidal neovascularization in younger patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6086222

15 October 2018

Expression of vascular endothelial growth factor in experimental choroidal neovascularization

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6086222

15 October 2018

Etiology of choroidal neovascularization in young patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6086222

15 October 2018

Ranibizumab Treatment for Choroidal Neovascularization from Causes Other than Age-Related Macular Degeneration and Pathological Myopia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6086222

3 December 2018

Intravitreal Bevacizumab in Inflammatory Ocular Neovascularization

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6086222

3 December 2018

Risk factors for choroidal neovascularization in young patients: a case-control study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6086222

3 December 2018

A randomized trial of intravitreal bevacizumab vs. ranibizumab for myopic CNV

1 reference

https://pubmed.ncbi.nlm.nih.gov/28704254

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Monthly Ranibizumab for Choroidal Neovascularizations Secondary to Angioid Streaks in Pseudoxanthoma Elasticum: A One-Year Prospective Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/28704254

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR NAIVE IDIOPATHIC CHOROIDAL NEOVASCULARIZATION: A Comparative Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/28704254

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study

1 reference

https://pubmed.ncbi.nlm.nih.gov/28704254

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized trial of intravitreal bevacizumab vs. ranibizumab for myopic CNV

1 reference

https://pubmed.ncbi.nlm.nih.gov/28704254

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intravitreal bevacizumab (avastin) for choroidal neovascularization secondary to central serous chorioretinopathy, secondary to punctate inner choroidopathy, or of idiopathic origin

1 reference

https://pubmed.ncbi.nlm.nih.gov/28704254

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Natural history of choroidal neovascularization induced by vascular endothelial growth factor in the primate

1 reference

https://pubmed.ncbi.nlm.nih.gov/28704254

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinicopathologic correlations of surgically excised type 1 and type 2 submacular choroidal neovascular membranes

1 reference

https://pubmed.ncbi.nlm.nih.gov/28704254

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Outcomes of anti-vascular endothelial growth factor therapy in the management of choroidal neovascularization associated with choroidal osteoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/28704254

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1097/IAE.0000000000001744

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

PMC publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38680981&oldid=1775958816"